858 Therapeutics
Chris Mcbride has over 20 years of work experience in the biopharmaceutical industry. Chris began their career in 1997 as a Specialist at Chiron Corporation. In 2006, they became a Staff Scientist at Takeda Pharmaceuticals and a Specialist at Novartis Institutes for BioMedical Research (NIBR). In 2016, they were promoted to Senior Scientist at Jecure Therapeutics. Most recently, they have been the Director at 858 Therapeutics since 2019.
Chris Mcbride completed a Bachelor of Science/Bachelor of Arts degree in Chemistry/Anthropology from the University of California, Santa Cruz in 1997, having started their studies there in 1993.
858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.